The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy).

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

In its update posted this morning, GSK revealed that sales of its Arexvy vaccine came in at £1.24 billion ($1.57 billion) in 2023, including £529 million ($671 million) from the fourth quarter.

Although it lowered its outlook for vaccines, including Arexvy, this was more than offset by new revenue contribution from oncology drug Blenrep and various late-stage pipeline assets. Although ...

The Therapeutic Goods Administration (TGA) has approved AREXVY to be used as a RSV vaccine for Australians aged 60 and over.

The Business Research Company's Abrysvo Or Arexvy Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 ...

GSK has historically been strong in vaccines and respiratory medicines. But Arexvy, its vaccine against respiratory syncytial virus, suffered a setback when a US immunisation advisory group ...